Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a leader in oncology immunotherapy, is set to present two studies on their drug pelareorep at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will highlight the drug’s potential in treating metastatic pancreatic, breast, and colon cancers, and its ability to transform ‘cold’ tumors into ‘hot’, enhancing immune response against cancer. The biotech firm is advancing towards registrational studies in metastatic breast and pancreatic cancers, both granted Fast Track designation by the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
